The Medicines Company Angiomax

FDA issues "approvable" letter May 11 for bivalirudin as an anticoagulant for patients with unstable angina undergoing percutaneous transluminal coronary angioplasty. In October 1998, FDA's Cardiovascular and Renal Drugs Advisory Committee declined to recommend the anticoagulant, formerly Hirulog, for approval (1"The Pink Sheet" Nov 2, 1998, p. 19)